<ul><li>NEC X, the Silicon Valley venture studio backed by NEC’s portfolio of advanced technologies and global businesses, has announced a new investment in General Prognostics Inc. (GPx), a MedTech startup revolutionizing chronic disease monitoring and management.</li><li>NEC X's investment in GPx aligns with their vision of leveraging technology to improve healthcare access and reduce system burdens for patients with chronic conditions.</li><li>GPx has joined the Elev X! Boost program, a venture initiative by NEC X, to enhance the accuracy of its flagship product, CardioID, and drive revenue growth, enter new markets, and secure further funding.</li><li>The CardioID system enables remote blood monitoring for heart failure patients by extracting biomarkers from wearable devices and utilizing advanced machine learning to develop predictive models.</li></ul>

NEC X Invests in GPx to Advance AI-Driven Chronic Disease Monitoring

Discover more